-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
July 30, 2021, the drug approval document pending information is released
Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
.
.
Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
Source: One-click search on Mi Nei.
com
com
At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
July 30, 2021, the drug approval document pending information is released
Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
.
.
Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
Source: One-click search on Mi Nei.
com
com
At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
.
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
.
July 30, 2021, the drug approval document pending information is released
Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
.
.
Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Menet.
com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
.
Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
.
Source: One-click search on Mi Nei.
com
com
At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
Enterprise business enterprise.
In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
.
In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
